佳人破瓜含羞叫床|久久婷五月天|国产熟女人妻一区二区三区四区 |久久久精品人妻一区二区

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73197KIF5B(E15)-RET(E12) V804E/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3
名稱 KIF5B(E15)-RET(E12) V804E/BaF3
型號(hào) CBP73197
報(bào)價(jià)
特點(diǎn) KIF5B(E15)-RET(E12) [V804E]/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73197
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804E]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804E]/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3


2. Sanger of KIF5B-RET [V804E]/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3

KIF5B(E15)-RET(E12) V804E/BaF3


3. Anti-proliferation assay

KIF5B(E15)-RET(E12) V804E/BaF3


Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804E Cells (C1).





如果你對(duì)CBP73197KIF5B(E15)-RET(E12) V804E/BaF3感興趣,想了解更詳細(xì)的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站

佳人破瓜含羞叫床|久久婷五月天|国产熟女人妻一区二区三区四区 |久久久精品人妻一区二区

色婷婷综合激情| 日韩欧美一区二区三区四区| av在线免费播放观看| 精品人妻一区二区三区线国色天香 | 四虎成人精品永久免费av| 中文字幕人妻av| 色之久久| jlzzjlzz亚洲女人水| 7788理论片在线观看| 国产精品人妻人伦a62v久网| 91精品久久久久久久久久久久久久 | 黄色片网站在线观看| 激情五月婷婷综合| 欧美精品无码一区二区三区| 国产人妻一区| 97人人做人人妻人人爽视频 | 欧美日韩精品在线视频| 精品一区二区三区18| 91国偷自产一区二区三区蜜臀 | 国产一级黄片大全| 欧美日韩在线综合| free×性老师vidos欧美| a人片中文字幕一区二区| 久久久久一区二区三区| videosgratis欧美极品| 少妇高潮时被猛烈进出的感觉怎么样| 人妻中文一区| 91av国产精品| 天堂草在线观看国产AV| 老熟女高潮喷水大叫| 日韩成人精品一区二区三区| 亚洲一区毛片| 欧美变态另类| 国产一区在线观看视频| 扒开腿添十八禁| 欧美激情视频在线| 欧美人妻一区二区三区88av| 国产又粗又猛又黄又爽无遮挡海宁 | JLZZ大全| 各种少妇正面bbw撒尿| 欧美少妇人妻|